ES2454773T3 - Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN - Google Patents

Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN Download PDF

Info

Publication number
ES2454773T3
ES2454773T3 ES08838119.9T ES08838119T ES2454773T3 ES 2454773 T3 ES2454773 T3 ES 2454773T3 ES 08838119 T ES08838119 T ES 08838119T ES 2454773 T3 ES2454773 T3 ES 2454773T3
Authority
ES
Spain
Prior art keywords
amino acid
polypeptide
seq
terminal end
aligned
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08838119.9T
Other languages
English (en)
Inventor
Stephen Cusack
Delphine Guilligay
Darren Hart
Franck Tarendeau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical Europaisches Laboratorium fuer Molekularbiologie EMBL
Application granted granted Critical
Publication of ES2454773T3 publication Critical patent/ES2454773T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D1/00Containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material, by deep-drawing operations performed on sheet material
    • B65D1/02Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
    • B65D1/0223Bottles or similar containers with necks or like restricted apertures, designed for pouring contents characterised by shape
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2501/00Containers having bodies formed in one piece
    • B65D2501/0009Bottles or similar containers with necks or like restricted apertures designed for pouring contents
    • B65D2501/0018Ribs
    • B65D2501/0036Hollow circonferential ribs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/11Orthomyxoviridae, e.g. influenza virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Ceramic Engineering (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Containers Having Bodies Formed In One Piece (AREA)

Abstract

Fragmento polipeptídico soluble de una subunidad PB2 de ARN-polimerasa dependiente de ARN del virus de la gripe, en que dicho fragmento polipeptídico soluble es seleccionado del grupo consistente en: (i) un fragmento polipeptídico cuyo extremo N-terminal está localizado en la posición de aminoácido 220 del polipéptido de PB2 conforme a la SEQ ID N.º 1 o en un residuo de aminoácido que ocupa una posición análoga en un polipéptido de PB2 alineado con ella o una posición de aminoácido superior; y cuyo extremo C-terminal está localizado en la posición de aminoácido 510 del polipéptido de PB2 conforme a la SEQ ID N.º 1 o en un residuo de aminoácido que ocupa una posición análoga en un polipéptido de PB2 alineado con ella o en una posición de aminoácido inferior; o (ii) un fragmento polipeptídico cuyo extremo N-terminal está localizado en la posición de aminoácido 222 del polipéptido de PB2 conforme a la SEQ ID N.º 2 o en un residuo de aminoácido que ocupa una posición análoga en un polipéptido de PB2 alineado con ella o una posición de aminoácido superior; y cuyo extremo C-terminal está localizado en la posición de aminoácido 511 del polipéptido de PB2 conforme a la SEQ ID N.º 2 o en un residuo de aminoácido que ocupa una posición análoga en un polipéptido de PB2 alineado con ella o en una posición de aminoácido inferior; o (iii) un fragmento polipeptídico cuyo extremo N-terminal está localizado en la posición de aminoácido 227 del polipéptido de PB2 conforme a la SEQ ID N.º 3 o en un residuo de aminoácido que ocupa una posición análoga en un polipéptido de PB2 alineado con ella o una posición de aminoácido superior; y cuyo extremo C-terminal está localizado en la posición de aminoácido 528 del polipéptido de PB2 conforme a la SEQ ID N.º 3 o en un residuo de aminoácido que ocupa una posición análoga en un polipéptido de PB2 alineado con ella o en una posición de aminoácido inferior; o (iv) un variante de fragmento polipeptídico, la cual mantiene una identidad de secuencia de como mínimo el 80% con el fragmento polipeptídico conforme a (i), (ii) o (iii) y en la cual el fragmento polipeptídico conforme a (i), (ii) o (iii) o la variante de fragmento polipeptídico conforme a (iv) conserva la capacidad para asociarse con un casquete de ARN o un análogo de éste; en que el análogo del casquete de ARN se selecciona del grupo consistente en m7G, m7GMP, m7GTP, m7GpppN, m7GpppNm.
ES08838119.9T 2007-10-09 2008-10-09 Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN Active ES2454773T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US70792P 1998-01-08
US99839807P 2007-10-09 2007-10-09
US998398P 2007-10-09
US7079208P 2008-03-25 2008-03-25
US12345608P 2008-04-08 2008-04-08
US123456P 2008-04-08
PCT/EP2008/008543 WO2009046983A1 (en) 2007-10-09 2008-10-09 Soluble fragments of influenza virus pb2 protein capable of binding rna-cap

Publications (1)

Publication Number Publication Date
ES2454773T3 true ES2454773T3 (es) 2014-04-11

Family

ID=40364724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08838119.9T Active ES2454773T3 (es) 2007-10-09 2008-10-09 Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN

Country Status (11)

Country Link
US (1) US9045248B2 (es)
EP (2) EP2197901B1 (es)
JP (3) JP5725861B2 (es)
KR (1) KR101672554B1 (es)
CN (1) CN101970465B (es)
AU (1) AU2008309939B2 (es)
CA (1) CA2701362A1 (es)
ES (1) ES2454773T3 (es)
IL (3) IL204891A (es)
SG (1) SG185289A1 (es)
WO (1) WO2009046983A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2701362A1 (en) 2007-10-09 2009-04-16 European Molecular Biology Laboratory (Embl) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
ES2604667T3 (es) 2009-06-17 2017-03-08 Vertex Pharmaceuticals Incorporated Inhibidores de la replicación de virus de influenza
WO2011113579A2 (en) * 2010-03-16 2011-09-22 European Molecular Biology Laboratory (Embl) Influenza a 2009 pandemic h1n1 polypeptide fragments comprising endonuclease activity and their use
CA2822057A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
MX2015000789A (es) * 2012-07-19 2015-05-07 Zoetis Llc Composiciones de virus de la gripe bovina.
MX2016006200A (es) 2013-11-13 2016-08-08 Vertex Pharma Metodos para preparar inhibidores de la replicacion de virus de influenza.
EP3068776B1 (en) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CN105018441A (zh) * 2014-04-22 2015-11-04 中国科学院生物物理研究所 流感病毒rna聚合酶结晶的方法
CN105002149B (zh) * 2014-04-22 2018-04-06 中国科学院生物物理研究所 流感病毒rna聚合酶纯化或结晶的方法
EP3294735B8 (en) 2015-05-13 2022-01-05 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
CN107286044B (zh) 2016-04-13 2021-07-13 香港神农有限公司 一种能够抑制流感病毒pb2蛋白与rna帽结合的化合物
CL2018003871A1 (es) * 2018-12-28 2021-01-15 Univ Pontificia Catolica Chile Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu
WO2020239822A1 (en) 2019-05-27 2020-12-03 The European Molecular Biology Laboratory Nucleic acid construct binding to influenza polymerase pb1 rna synthesis active site
CN113337558A (zh) * 2020-08-20 2021-09-03 深圳市瑞吉生物科技有限公司 一种Cap2结构5`帽子类似物及其制备方法和应用
CN114741315B (zh) * 2022-04-28 2023-06-13 深圳市紫光同创电子有限公司 用例更新方法、装置、电子设备及存储介质

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837852A (en) * 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
CA2701362A1 (en) 2007-10-09 2009-04-16 European Molecular Biology Laboratory (Embl) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
JP6614523B2 (ja) * 2014-03-28 2019-12-04 地方独立行政法人神奈川県立産業技術総合研究所 インフルエンザウイルスのrna依存性rnaポリメラーゼのpb2サブユニットに対するモノクローナル抗体

Also Published As

Publication number Publication date
EP2197901A1 (en) 2010-06-23
EP2574619A3 (en) 2013-07-31
SG185289A1 (en) 2012-11-29
JP6309563B2 (ja) 2018-04-11
AU2008309939A1 (en) 2009-04-16
CA2701362A1 (en) 2009-04-16
JP5937169B2 (ja) 2016-06-22
IL222997A0 (en) 2012-12-31
CN101970465B (zh) 2016-03-16
JP2015062417A (ja) 2015-04-09
KR101672554B1 (ko) 2016-11-03
IL237903A (en) 2017-10-31
IL204891A0 (en) 2010-11-30
CN101970465A (zh) 2011-02-09
WO2009046983A1 (en) 2009-04-16
JP5725861B2 (ja) 2015-05-27
KR20100074212A (ko) 2010-07-01
US20110008348A1 (en) 2011-01-13
US9045248B2 (en) 2015-06-02
IL204891A (en) 2015-04-30
EP2197901B1 (en) 2013-12-11
JP2011501942A (ja) 2011-01-20
AU2008309939B2 (en) 2013-11-14
EP2574619A2 (en) 2013-04-03
JP2016176955A (ja) 2016-10-06

Similar Documents

Publication Publication Date Title
ES2454773T3 (es) Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN
ES2545895T3 (es) Proteína de fusión anticancerígena
BR112018070637A2 (pt) receptores de células t
MX2017016101A (es) Polinucleotidos y polipetidos de adenovirus.
BR112018070600A2 (pt) receptores de células t
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
JP2014195454A5 (es)
PE20120817A1 (es) Peptidos tau antigenicos y usos de los mismos
PE20170950A1 (es) Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos
ES2531288T3 (es) Proteína de fusión anticancerígena
ES2691091T3 (es) Vacuna conjugada de péptido antigénico de WT1
CY1119916T1 (el) Ανοσογονικη συνθεση
PE20081723A1 (es) Vacuna contra el papilomavirus
AR072009A1 (es) Mutantes del factor de crecimiento de los fibroblastos fgf21 y usos de los mismos
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
NZ627111A (en) Variants of activin iib receptor polypeptides and uses thereof
CO6150187A2 (es) Vacunas para malaria
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
MX2019008949A (es) Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
AR075932A1 (es) Proteasa coagulante de leche de tipo mejorado derivada del microorganismo rhizomucor sp
AR074055A1 (es) Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
WO2015107363A3 (en) Mycobacterial antigen composition
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina